Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients.
Davide BosettiChiara BernardiMarie MauliniFederica GiannottiAnne-Claire MamezStavroula Masouridi-LevratYves ChalandonDionysios NeofytosPublished in: Antimicrobial agents and chemotherapy (2023)
We present two allogeneic hematopoietic cell transplantation recipients (HCTr) treated with pritelivir for acyclovir-resistant/refractory (r/r) HSV infection based on the expanded access program of the pritelivir manufacturer. Outpatient treatment with pritelivir was administered, with partial response by week 1 of treatment and complete response by week 4 of treatment in both patients. No adverse events were noted. Pritelivir appears to be an effective and safe option for the management of acyclovir-r/r HSV infections in highly immunocompromised patients in an outpatient setting.
Keyphrases
- end stage renal disease
- newly diagnosed
- clinical trial
- bone marrow
- chronic kidney disease
- herpes simplex virus
- intensive care unit
- stem cells
- stem cell transplantation
- peritoneal dialysis
- ejection fraction
- single cell
- combination therapy
- low dose
- patient reported outcomes
- study protocol
- smoking cessation
- mechanical ventilation